Anita Mitchell1, Richard W Hall2, Stephen W Erickson3, Charlotte Yates4, Scott Lowery, Howard Hendrickson5. 1. a Department of Nursing Science , College of Nursing, University of Arkansas for Medical Sciences , Little Rock , AR , USA. 2. b Department of Pediatrics , College of Medicine, University of Arkansas for Medical Sciences , Little Rock , AR , USA. 3. c Department of Biostatistics , University of Arkansas for Medical Sciences , Little Rock , AR , USA. 4. d Department of Physical Therapy , University of Central Arkansas , Conway , AR , USA. 5. e Department of Pharmaceutical Sciences , College of Pharmacy, University of Arkansas for Medical Sciences , Little Rock , AR , USA.
Abstract
PURPOSE:Preterm infants undergoing Retinopathy of Prematurity Eye Exams (ROPEE) may experience adverse events, possibly from systemic absorption of cyclopentolate. The purpose of this study was to analyze the association between adverse events and drug levels found in neonates undergoing ROPEE. MATERIALS AND METHODS:25 infants were randomized into two groups during routine ROP screening: 5 infants for blood collection before mydriatic drops and 20 for blood collection 1 h after eye drops. Blood was collected onto dried blood spot cards, extracted, and analyzed for cyclopentolate and phenylephrine using liquid chromatography and mass spectrometry. Relationships between drug levels and adverse events were assessed. RESULTS:Cyclopentolate (range 6-53 ng/ml) was observed in 15 of 18 infants, while phenylephrine was not detected. Levels of cyclopentolate were significantly higher in infants who were on oxygen (p = 0.01). There was a significant association between cyclopentolate levels and gastric residuals in tube-fed infants not receiving oxygen (p = 0.01). CONCLUSIONS:Cyclopentolate levels varied among preterm infants after ROPEE. Cyclopentolate was positively associated with increased gastric residuals. Underlying medical conditions requiring oxygen administration may affect absorption and metabolism of cyclopentolate. There is a need to predict infants at risk for high blood levels of cyclopentolate in order to prevent or treat adverse events after ROPEE.
RCT Entities:
PURPOSE: Preterm infants undergoing Retinopathy of Prematurity Eye Exams (ROPEE) may experience adverse events, possibly from systemic absorption of cyclopentolate. The purpose of this study was to analyze the association between adverse events and drug levels found in neonates undergoing ROPEE. MATERIALS AND METHODS: 25 infants were randomized into two groups during routine ROP screening: 5 infants for blood collection before mydriatic drops and 20 for blood collection 1 h after eye drops. Blood was collected onto dried blood spot cards, extracted, and analyzed for cyclopentolate and phenylephrine using liquid chromatography and mass spectrometry. Relationships between drug levels and adverse events were assessed. RESULTS:Cyclopentolate (range 6-53 ng/ml) was observed in 15 of 18 infants, while phenylephrine was not detected. Levels of cyclopentolate were significantly higher in infants who were on oxygen (p = 0.01). There was a significant association between cyclopentolate levels and gastric residuals in tube-fed infants not receiving oxygen (p = 0.01). CONCLUSIONS:Cyclopentolate levels varied among preterm infants after ROPEE. Cyclopentolate was positively associated with increased gastric residuals. Underlying medical conditions requiring oxygen administration may affect absorption and metabolism of cyclopentolate. There is a need to predict infants at risk for high blood levels of cyclopentolate in order to prevent or treat adverse events after ROPEE.
Authors: D Fanni; R Ambu; C Gerosa; S Nemolato; M Castagnola; P Van Eyken; G Faa; V Fanos Journal: Int J Immunopathol Pharmacol Date: 2014 Jan-Mar Impact factor: 3.219
Authors: Dan Ni Wang; Kyla Lavery; Stacey Dalgleish; Alexandra Howlett; Vivian E Hill; Stephanie A Dotchin Journal: J Perinatol Date: 2020-10-15 Impact factor: 2.521
Authors: John B C Tan; Jennifer Dunbar; Andrew Hopper; Christopher G Wilson; Danilyn M Angeles Journal: J Perinatol Date: 2019-02-12 Impact factor: 2.521
Authors: Ronald H Silverman; Raksha Urs; Danny H-Kauffmann Jokl; Leora Pinto; Osode Coki; Rakesh Sahni; Jason D Horowitz; Steven E Brooks Journal: Transl Vis Sci Technol Date: 2021-02-05 Impact factor: 3.048
Authors: Iason S Mantagos; Carolyn Wu; Joseph F Griffith; Benjamin G Jastrzembski; Efren Gonzalez; Samantha Goldstein; Lori Pearlo; Deborah K Vanderveen Journal: J AAPOS Date: 2021-04-18 Impact factor: 1.220
Authors: Francesco Semeraro; Eliana Forbice; Giuseppe Nascimbeni; Salvatore Cillino; Vincenza Maria Elena Bonfiglio; Maria Elena Filippelli; Silvia Bartollino; Ciro Costagliola Journal: Front Pediatr Date: 2020-01-29 Impact factor: 3.418